^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Elrexfio (elranatamab-bcmm)

    i
    Other names: PF-06863135, PF 06863135, PF06863135, PF‑3135, PF3135, RN 613, RN613, RN-613
    Company:
    Pfizer
    Drug class:
    CD3 agonist, BCMA inhibitor
    Related drugs:
    11d
    MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, Pfizer | N=34 --> 46
    Enrollment change
    |
    lenalidomide • dexamethasone • Elrexfio (elranatamab-bcmm) • Ogsiveo (nirogacestat)
    17d
    CA057-1040: Phase 1b/2a Study to Evaluate Mezigdomide in Combination with Elranatamab in Relapsed and/or Refractory Multiple Myeloma (2025-522090-11-00)
    P1/2, N=24, Recruiting, Celgene Corp.
    New P1/2 trial
    |
    dexamethasone • Elrexfio (elranatamab-bcmm) • mezigdomide (CC-92480)
    24d
    MagnetisMM-9: A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment (clinicaltrials.gov)
    P2, N=86, Completed, Pfizer | Active, not recruiting --> Completed
    Trial completion
    |
    Elrexfio (elranatamab-bcmm)
    29d
    A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Pfizer
    New trial • Real-world evidence
    |
    Elrexfio (elranatamab-bcmm)
    1m
    A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    Elrexfio (elranatamab-bcmm)
    1m
    Synergistic effects of elranatamab and Juzentaihoto, Japanese traditional herbal medicine, in triple-class-exposed relapsed/refractory multiple myeloma with extramedullary disease: a case report. (PubMed, Int J Hematol)
    JTT may enhance the efficacy of T cell-redirecting immunotherapies in RRMM by promoting cytotoxic T cell expansion. These findings warrant further investigation into the use of JTT as an adjunct to improve outcomes in patients with EMD.
    Journal
    |
    CD4 (CD4 Molecule)
    |
    Elrexfio (elranatamab-bcmm)
    1m
    A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects (clinicaltrials.gov)
    P1, N=60, Recruiting, C4 Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Elrexfio (elranatamab-bcmm) • cemsidomide (CFT7455)
    2ms
    Case Report: autologous stem cell boost enables hematopoietic recovery after severe cytopenia induced by BCMA-targeted bispecific antibody therapy in multiple myeloma. (PubMed, Front Oncol)
    Neutrophil recovery occurred by day +10, transfusion independence by day +19, and hematologic recovery allowed elranatamab resumption without recurrence of severe cytopenia. This case demonstrates the potential utility of SCB for managing persistent cytopenias after T-cell-redirecting therapies and supports the importance of early stem cell collection.
    Journal
    |
    CD34 (CD34 molecule)
    |
    Elrexfio (elranatamab-bcmm)
    2ms
    BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape. (PubMed, Semin Hematol)
    We then summarize the clinical development and distinguishing features of currently approved BCMA-targeted modalities-CAR T-cell therapies (ide-cel, cilta-cel), bispecific T-cell engagers (teclistamab, elranatamab, linvoseltamab), and the antibody-drug conjugate (belantamab mafodotin)-highlighting their efficacy, toxicity profiles, and practical positioning in relapsed/refractory MM. Finally, we review emerging resistance mechanisms, including γ-secretase-driven sBCMA elevation, ligand-rich APRIL/BAFF niches, and therapy-induced TNFRSF17 lesions, ranging from biallelic deletions to epitope-altering missense mutations and in-frame deletions within the BCMA extracellular domain. These insights inform rational strategies such as γ-secretase inhibition, dual-target CAR T-cells and bispecific T-cell engagers.
    Journal • IO biomarker
    |
    TNFRSF17 (TNF Receptor Superfamily Member 17)
    |
    Elrexfio (elranatamab-bcmm) • Blenrep (belantamab mafodotin-blmf) • Abecma (idecabtagene vicleucel) • Carvykti (ciltacabtagene autoleucel) • Tecvayli (teclistamab-cqyv) • Lynozyfic (linvoseltamab-gcpt)
    2ms
    MAGNETISMM-5: A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments (clinicaltrials.gov)
    P3, N=944, Recruiting, Pfizer | Trial primary completion date: Dec 2025 --> Apr 2026
    Trial primary completion date
    |
    lenalidomide • dexamethasone • pomalidomide • Elrexfio (elranatamab-bcmm) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2ms
    MagnetisMM-6: A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy (clinicaltrials.gov)
    P3, N=1116, Recruiting, Pfizer | Trial completion date: Nov 2031 --> Oct 2033 | Trial primary completion date: Mar 2028 --> Oct 2030
    Trial completion date • Trial primary completion date
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone • Elrexfio (elranatamab-bcmm)
    2ms
    ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab (clinicaltrials.gov)
    P=N/A, N=159, Not yet recruiting, Peking University People's Hospital
    New trial
    |
    Elrexfio (elranatamab-bcmm)